Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 11Active not recruiting 9Not yet recruiting 3Terminated 2Completed 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 66Cyclophosphamide 44Cisplatin 43Nivolumab 36Paclitaxel 32Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Doxorubicin 19Bevacizumab 19Magnetic Resonance Spectroscopy 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Radiosurgery 15Letrozole 15Ipilimumab 15Fluorouracil 15Blood Specimen Collection 15palbociclib 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14Surveys and Questionnaires 13Specimen Handling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Idarubicin × 90 days × Clear all
NCT02688140 2026-05-29

TUD-APOLLO-064

Technische Universität Dresden

Phase 3 Completed
133 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04107727 2026-03-24

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 2 Completed
273 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡